Pharsight

Tekturna Hct patents expiration

TEKTURNA HCT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023893 NODEN PHARMA Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Mar, 2022

(1 year, 6 months ago)

US8618172 NODEN PHARMA Galenical formulations of organic compounds
Jul, 2028

(4 years from now)

Tekturna Hct is owned by Noden Pharma.

Tekturna Hct contains Aliskiren Hemifumarate; Hydrochlorothiazide.

Tekturna Hct has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Tekturna Hct are:

  • US9023893

Tekturna Hct was authorised for market use on 18 January, 2008.

Tekturna Hct is available in tablet;oral dosage forms.

The generics of Tekturna Hct are possible to be released after 13 July, 2028.

Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient

Market Authorisation Date: 18 January, 2008

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TEKTURNA HCT before it's drug patent expiration?
More Information on Dosage

TEKTURNA HCT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic